Table 2.
Adjusted Associations of 45-Day Severe Outcomes of Patients Testing Positive for SARS-CoV-2. N = 39,686
| Any outcome OR (95% CI) N = 3977 |
Hospitalization OR (95% CI) N = 3819 |
ICU admission OR (95% CI) N = 991 |
Death OR (95% CI) N = 600 |
|
|---|---|---|---|---|
| Medication class (vs none) | ||||
| Prednisone | 1.31 (1.08–1.60) | 1.32 (1.08–1.60) | 1.84 (1.38–2.46) | 1.70 (1.17–2.47) |
| Conventional immunomodulator | 0.88 (0.57–1.34) | 0.99 (0.65–1.51) | 0.95 (0.49–1.85) | 1.71 (0.85–3.47) |
| Small molecule or biologic | 1.26 (0.79–2.00) | 1.27 (0.80–2.01) | 1.32 (0.64–2.69) | 1.51 (0.66–3.48) |
| Immune condition (vs none) | ||||
| Asthma | 1.08 (0.98–1.20) | 1.11 (1.00–1.23) | 1.10 (0.92–1.32) | 0.85 (0.67–1.07) |
| Inflammatory bowel disease | 1.22 (0.82–1.81) | 1.15 (0.77–1.72) | 0.83 (0.41–1.69) | 0.76 (0.35–1.68) |
| Organ transplantation | 1.84 (1.00–3.40) | 1.86 (1.01–3.40) | 1.58 (0.67–3.71) | 0.69 (0.24–1.95) |
| Psoriasis | 1.15 (0.89–1.49) | 1.17 (0.90–1.51) | 1.63 (1.10–2.39) | 0.92 (0.53–1.58) |
| Spondyloarthopathy | 0.37 (0.14–0.97) | 0.38 (0.15–0.99) | 0.19 (0.02–1.51) | 0.37 (0.04–3.08) |
| Rheumatoid arthritis | 0.95 (0.66–1.36) | 0.93 (0.65–1.34) | 0.97 (0.55–1.69) | 0.67 (0.36–1.24) |
| Systemic lupus erythematosis | 1.22 (0.53–2.83) | 1.31 (0.57–2.99) | 1.11 (0.32–3.80) | 1.00 (0.25–4.00) |
| Charlson comorbidity score | 1.15 (1.13–1.18) | 1.12 (1.09–1.14) | 1.07 (1.04–1.11) | 1.18 (1.14–1.23) |
| Hypertension | 3.19 (2.88–3.53) | 3.28 (2.95–3.63) | 3.31 (2.80–3.91) | 2.24 (1.83–2.73) |
| Female (vs. male) | 0.68 (0.63–0.73) | 0.67 (0.63–0.73) | 0.46 (0.40–0.53) | 0.63 (0.53–0.75) |
| Age, years | ||||
| 18–29 | 0.48 (0.42–0.56) | 0.48 (0.42–0.56) | 0.41 (0.29–0.58) | 0.31 (0.11–0.89) |
| 30–49 | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) |
| 50–65 | 2.00 (1.83–2.20) | 2.02 (1.84–2.22) | 2.55 (2.13–3.06) | 7.03 (4.52–10.94) |
| > 65 | 4.87 (4.35–5.45) | 4.52 (4.03–5.06) | 4.66 (3.77–5.75) | 32.91 (21.30–50.84) |
| Race/ethnicity | ||||
| Asian | 1.74 (1.53–1.98) | 1.82 (1.60–2.07) | 2.07 (1.63–2.63) | 0.82 (0.61–1.10) |
| Black | 1.55 (1.34–1.80) | 1.60 (1.38–1.86) | 1.84 (1.41–2.39) | 1.03 (0.76–1.40) |
| Hispanic | 1.43 (1.29–1.58) | 1.49 (1.35–1.64) | 2.02 (1.68–2.44) | 0.89 (0.71–1.11) |
| White | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) |
| Other/unknown | 1.18 (1.01–1.37) | 1.18 (1.01–1.38) | 1.55 (1.16–2.06) | 0.99 (0.70–1.39) |
| Body mass index* | ||||
| Underweight | 2.20 (1.57–3.10) | 1.47 (1.02–2.12) | 1.31 (0.71–2.45) | 3.13 (2.00–4.92) |
| Normal weight | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) |
| Overweight | 0.97 (0.86–1.09) | 1.03 (0.92–1.17) | 1.06 (0.86–1.32) | 0.55 (0.43–0.70) |
| Obese | 1.60 (1.43–1.79) | 1.72 (1.53–1.92) | 1.66 (1.35–2.04) | 0.81 (0.65–1.02) |
All models also adjust for week of SARS-CoV-2-positive lab test
*Also adjusts for missing/unknown status